356068-94-5 | Toceranib

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$11.00	$8.00
5mg	97%	in stock	$13.00	$9.00
10mg	97%	in stock	$16.00	$11.00
25mg	97%	in stock	$19.00	$13.00
50mg	97%	in stock	$23.00	$16.00
250mg	97%	in stock	$45.00	$32.00
1g	97%	in stock	$103.00	$72.00
5g	97%	in stock	$309.00	$216.00
25g	97%	in stock	$1,317.00	$922.00

Description

• Catalog Number: AF68098
• Chemical Name: Toceranib
• CAS Number: 356068-94-5
• Molecular Formula: C22H25FN4O2
• Molecular Weight: 396.4579
• MDL Number: MFCD16038046
• SMILES: Fc1ccc2c(c1)/C(=C/c1[nH]c(c(c1C)C(=O)NCCN1CCCC1)C)/C(=O)N2

Computed Properties

• Complexity: 663
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 5
• XLogP3: 2.4

Literature

• Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

  Veterinary and comparative oncology 20120901

• Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.

  Veterinary and comparative oncology 20120901

• Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib.

  Veterinary and comparative oncology 20120901

• Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

  Veterinary and comparative oncology 20120901

• Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.

  Veterinary and comparative oncology 20120901

• Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

  Journal of veterinary internal medicine 20120101

• Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.

  Journal of veterinary internal medicine 20120101

• Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.

  Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association 20120101

• Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.

  Veterinary and comparative oncology 20100901

• Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.

  Journal of veterinary pharmacology and therapeutics 20100401

• Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.

  Journal of veterinary pharmacology and therapeutics 20100401

• Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031115

• Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

  Journal of medicinal chemistry 20030327

• Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

  Blood 20020715